Pharvaris (NASDAQ:PHVS) Short Interest Update

by · The Cerbat Gem

Pharvaris (NASDAQ:PHVS – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 131,800 shares, a decline of 83.8% from the September 30th total of 813,000 shares. Based on an average trading volume of 99,200 shares, the short-interest ratio is presently 1.3 days. Currently, 0.7% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Oppenheimer lifted their target price on shares of Pharvaris from $38.00 to $42.00 and gave the company an “outperform” rating in a report on Friday, September 6th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.60.

Read Our Latest Stock Report on Pharvaris

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the business. Sofinnova Investments Inc. lifted its holdings in shares of Pharvaris by 2.9% in the second quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock valued at $11,309,000 after purchasing an additional 16,862 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of Pharvaris by 31.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after purchasing an additional 335,687 shares in the last quarter. Finally, Novo Holdings A S lifted its holdings in shares of Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after purchasing an additional 556,970 shares in the last quarter.

Pharvaris Stock Up 1.8 %

PHVS stock traded up $0.38 during trading on Friday, reaching $21.71. 11,126 shares of the company were exchanged, compared to its average volume of 89,099. Pharvaris has a 52-week low of $15.00 and a 52-week high of $33.00. The stock’s 50 day moving average price is $19.35 and its 200 day moving average price is $19.26.

Pharvaris (NASDAQ:PHVS – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). On average, research analysts expect that Pharvaris will post -2.63 earnings per share for the current fiscal year.

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

See Also